Injective feels like one of those chains that quietly earns its place instead of screaming for it. While most L1s are still trying to prove they matter, @Injective is already settling real volume with sub-second finality, deep staking, and a growing base of real users—not just speculators rotating in and out. The EVM launch, cross-chain connectivity, and on-chain orderbook infra make it feel less like “another alt L1” and more like a home base for serious markets.
I’m not here to guess exact targets, but I do know this: every month it gets harder to argue that $INJ is overpriced, and easier to see it as under-known.
